Core Insights - The medical device industry is facing a "tool gap" between hardware evolution and backend service support capabilities, leading to a fusion ecosystem of "hardware + services + intelligence" as a key strategy for companies to build competitive advantages [1] - Xiangsheng Medical has launched its self-developed AI assistant application, CHISON Pilot, globally, marking a significant leap in its service support system following the smart upgrade of ultrasound mainframes [1][2] Group 1: AI Assistant CHISON Pilot - CHISON Pilot is designed to bridge the gap between advanced hardware and fragmented support services, providing real-time, precise, and personalized information integration and decision support for sales, clinical, and end-users [2] - The application is available on Google Play and Apple App Store, covering 176 countries and regions, and is not just a simple tool but a critical product aimed at enhancing service efficiency [2][3] - CHISON Pilot features three intelligent modules that deliver differentiated value in sales support, clinical assistance, and user services, evolving from a passive tool to an active AI partner that understands user preferences over time [3] Group 2: SonoAI and Intelligent Service Ecosystem - Xiangsheng Medical has established a comprehensive intelligent standard framework for ultrasound AI diagnosis, driven by a dual-engine approach of "ultrasound AI + specialized models," covering the entire process from equipment development to diagnostic decision-making [4] - The SonoAI solution has been integrated into the SonoFamily product line, enabling intelligent scanning, precise measurement, assisted diagnosis, and automated reporting across key clinical areas [4] - The company has made significant advancements in breast ultrasound AI diagnostic systems, achieving improved accuracy in BI-RADS classification and benign/malignant differentiation, supporting large-scale breast cancer screening with high sensitivity and specificity [4][5] Group 3: Strategic Implications - The continuous launch of intelligent solutions like SonoAI and CHISON Pilot is helping Xiangsheng Medical build a closed-loop intelligent ecosystem from hardware to services, enhancing product competitiveness and pushing ultrasound medicine towards standardized, replicable intelligent decision-making [5] - The company's ongoing technological innovations in AI applications are reshaping the application paradigm and value boundaries of ultrasound devices, injecting new momentum into its global market expansion [5]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][9] Core Insights - The company is a pioneer in the ultrasound field, focusing on portable and intelligent solutions, with a strong outlook for external collaborations [2][8] - The company has a comprehensive product lineup that includes high-end ultrasound machines and portable devices, which are competitive in both domestic and international markets [8][60] - The financial projections indicate steady revenue growth, with expected revenues of 5.17 billion, 6.21 billion, and 7.45 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 1.46 billion, 1.82 billion, and 2.29 billion yuan [7][9] Summary by Sections 1. Company Overview - Founded in 1996, the company has focused on ultrasound technology, holding over 400 intellectual property rights and exporting products to more than 100 countries [18][21] - The company has established R&D centers in both China and the US, and has been involved in significant national research projects [18] 2. Market Potential - The global ultrasound market is projected to grow, with a compound annual growth rate (CAGR) of 9% expected from 2020 to 2024 [43] - The domestic ultrasound market is also expanding, with significant breakthroughs from local companies [47] 3. Product Development - The company has developed a complete range of ultrasound products, including high-end and portable devices, which are recognized for their performance and innovation [60][67] - The SonoFamily series includes advanced products like XBit90, SonoMax, SonoAir, and SonoEye, which leverage AI technology for enhanced diagnostic capabilities [60][66] 4. Financial Performance - The company has shown stable financial performance, with a projected revenue of 4.69 billion yuan in 2024, despite a slight decline due to external factors [27][32] - The gross margin remains stable at around 59%, with a low debt ratio of 11% as of Q3 2025 [34][38] 5. Strategic Collaborations - The company is actively pursuing external collaborations, including ODM partnerships with major global firms like Philips and the Gates Foundation, which are expected to enhance growth prospects [79][81]